Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
40.25 32.67 46.83 37.33

+8 more quarters

P/S ratio
13.44 11.39 14.79 11.52
P/FCF ratio
52.49 58.67 86.31 59.65
P/Operating CF
100.13 154.27 299.05 77.45
P/B ratio
31.59 26.37 36.34 28.69
EV/Sales
14.01 11.88 15.34 12.13
EV/EBITDA
31.24 25.58 35.32 29.38
EV/FCF
54.75 61.21 89.46 62.85
Current Ratio
1.35 1.50 1.58 1.55
Net Debt/EBITDA
4.83 3.62 3.93 3.95
Debt/Equity
1.62 1.26 1.60 1.71
Earnings Yield
2.48% 3.06% 2.14% 2.68%
Free Cash Flow Yield
1.91% 1.70% 1.16% 1.68%
Free Cash Flow per Share
8.69 3.36 0.76 7.52
Book value per Share
37.96 34.88 29.57 26.59
Free Cash Flow
7,757.00 3,007.00 677.90 6,748.10
EV/EBIT
33.19 27.23 38.00 31.85
Other line items

Show all line items

Columns are period end dates